Literature DB >> 28926544

CMTM6 controls PD-L1.

Ioana Visan.   

Abstract

Entities:  

Year:  2017        PMID： 28926544     DOI： 10.1038/ni.3844

Source DB:  PubMed          Journal:  Nat Immunol        ISSN： 1529-2908            Impact factor:   25.606


× No keyword cloud information.
  5 in total

Review 1.  CMTM6, a potential immunotherapy target.

Authors:  Jie Liang; Shaohua Li; Wei Li; Wei Rao; Shuo Xu; Haining Meng; Fengqi Zhu; Dongchang Zhai; Mengli Cui; Dan Xu; Jinzhen Cai; Bei Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2021-11-16       Impact factor: 4.553

2.  Identification of chemical compounds regulating PD-L1 by introducing HiBiT-tagged cells.

Authors:  Yutaro Uchida; Takahide Matsushima; Ryota Kurimoto; Tomoki Chiba; Yuki Inutani; Hiroshi Asahara
Journal:  FEBS Lett       Date:  2021-01-20       Impact factor: 4.124

Review 3.  Recent Findings in the Regulation of Programmed Death Ligand 1 Expression.

Authors:  Xiangfeng Shen; Lihong Zhang; Jicheng Li; Yulin Li; Yishu Wang; Zhi-Xiang Xu
Journal:  Front Immunol       Date:  2019-06-14       Impact factor: 7.561

4.  CMTM6 knockdown prevents glioma progression by inactivating the mTOR pathway.

Authors:  Li Wei; Qianfeng Wei; Xiaojun Yang; Peng Zhou
Journal:  Ann Transl Med       Date:  2022-02

Review 5.  Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.

Authors:  Ioannis Zerdes; Alexios Matikas; Jonas Bergh; George Z Rassidakis; Theodoros Foukakis
Journal:  Oncogene       Date:  2018-05-16       Impact factor: 9.867
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.